Promising breast cancer drug study halted early
Disease control
Terminated
This study tested a new drug called lerociclib combined with standard hormone therapy for people with a certain type of advanced breast cancer (HR+/HER2-). It aimed to see if the combination was safe and effective for those newly diagnosed or whose cancer had worsened after initi…
Phase: PHASE2 • Sponsor: EQRx, Inc. • Aim: Disease control
Last updated May 17, 2026 07:38 UTC